Dose dependency between cigarette consumption and reduced maternal serum PAPP-A levels at 11-13+6 weeks of gestation

Prenatal Diagnosis

Volumn 27, Issue 9, 2007, Pages 849-853

  Kagan, K O ^a   Frisova, V ^a   Nicolaides, K H ^a   Spencer, K ^a,b,c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b HAROLD WOOD HOSPITAL   (United Kingdom)

^c KING GEORGE HOSPITAL   (United Kingdom)

Author keywords

Free hCG; Maternal serum biochemistry; PAPP A; Screening; Smoking; Trisomy

Indexed keywords

CHORIONIC GONADOTROPIN BETA SUBUNIT; PREGNANCY ASSOCIATED PLASMA PROTEIN A;

ARTICLE; CIGARETTE SMOKING; DOWN SYNDROME; FEMALE; FIRST TRIMESTER PREGNANCY; HUMAN; MATERNAL SERUM; NUCHAL TRANSLUCENCY MEASUREMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCREENING;

ADOLESCENT; ADULT; CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN SYNDROME; FEMALE; HUMANS; MIDDLE AGED; NUCHAL TRANSLUCENCY MEASUREMENT; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PREGNANCY-ASSOCIATED PLASMA PROTEIN-A; RETROSPECTIVE STUDIES; SMOKING;

EID: 34548732390     PISSN: 01973851     EISSN: 10970223     Source Type: Journal    
DOI: 10.1002/pd.1793     Document Type: Article

References (27)

1. Avgidou K, Papageorghiou A, Bindra R, Spencer K, Nicolaides KH. 2005. Prospective first-trimester screening for trisomy 21 in 30,564 pregnancies. Am J Obstet Gynecol 192: 1761-1767.
2. Bonno M, Oxvig C, Kephart GM, et al. 1994. Localization of pregnancy-associated plasma protein-A and colocalization of pregnancy-associated plasma protein-A messenger ribonucleic acid and eosinophil granule major basic protein messenger ribonucleic acid in placenta. Lab Invest 71: 560-566.
3. Boyd NR, Windsor RA, Perkings LL, Lowe JB. 1998. Quality of measurement of smoking status by self-report and saliva cotinine among pregnant women. Matern Child Health J 2: 77-83.
4. Canick JA, Lambert-Messerlian GM, Palomaki GE, et al. 2006. Comparison of serum markers in first-trimester Down syndrome screening. Obstet Gynecol 108: 1192-1199.
5. Cuckle HS, Wald NJ, Thompson SG. 1987. Estimating a woman's risk of having a pregnancy associated with Down's syndrome using her age and serum alpha-fetoprotein level. Br J Obstet Gynaecol 94: 387-402.
6. De Graaf I, Cuckle HS, Pajkrt E, Leschot NJ, Bleker OP, van Lith JM. 2000. Co-variables in first trimester maternal serum screening. Prenat Diagn 20: 186-189.
7. Jauniaux E, Burton GJ. 1992. The effect of smoking in pregnancy on early placental morphology. Obstet Gynecol 79: 645-648.
8. Kendrick JS, Zahniser SC, Miller N, et al. 1995. Integrating smoking cessation into routine public prenatal care: the Smoking Cessation in Pregnancy project. Am J Public Health 85: 1451-1452.
9. Liao AW, Heath V, Kametas N, Spencer K, Nicolaides KH. 2001. First-trimester screening for trisomy 21 in singleton pregnancies achieved by assisted reproduction. Hum Reprod 16: 1501-1504.
10. Nicolaides KH, Spencer K, Avgidou K, Faiola S, Falcon O. 2005. Multicenter study of first-trimester screening for trisomy 21 in 75 821 pregnancies: results and estimation of the potential impact of individual risk-orientated two-stage first-trimester screening. Ultrasound Obstet Gynecol 25: 221-226.
11. Niemimaa M, Heinonen S, Seppala M, Ryynanen M. 2003. The influence of smoking on the pregnancy-associated plasma protein A, free beta human chorionic gonadotrophin and nuchal translucency. BJOG 110: 664-667.
12. Pickett KE, Wakschlag LS, Dai L, Leventhal BL. 2003. Fluctuations of maternal smoking during pregnancy. Obstet Gynecol 101: 140-147.
13. Royston P, Thompson SG. 1992. Model based screening by risk with application to Down's syndrome. Stat Med 11: 257-268.
14. Snijders RJM, Noble P, Sebire N, Souka A. 1998. Nicolaides KH. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation. Fetal Medicine Foundation First Trimester Screening Group. Lancet 352: 343-346.
15. Spencer K. 1998. The influence of smoking on maternal serum AFP and free beta hCG levels and the impact on screening for Down syndrome. Prenat Diagn 18: 225-234.
16. Spencer K. 1999. The influence of smoking on maternal serum PAPP-A and free beta hCG levels in the first trimester of pregnancy. Prenat Diagn 19: 1065-1066.
17. Spencer K. 2000. Screening for trisomy 21 in twin pregnancies in the first trimester using free beta-hCG and PAPP-A, combined with fetal nuchal translucency thickness. Prenat Diagn 20: 915.
18. Spencer K, Bindra R, Cacho AM, Nicolaides KH. 2004. The impact of correcting for smoking status when screening for chromosomal anomalies using maternal serum biochemistry and fetal nuchal translucency thickness in the first trimester of pregnancy. Prenat Diagn 24: 169-173.
19. Spencer K, Souter V, Tul N, Snijders R, Nicolaides KH. 1999. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A. Ultrasound Obstet Gynecol 13: 231-237.
20. Spencer K, Ong CY, Liao AW, Nicolaides KH. 2000a. The influence of ethnic origin on first trimester biochemical markers of chromosomal abnormalities. Prenat Diagn 20: 491-494.
21. Spencer K, Ong CY, Liao AWJ, Papademetriou D, Nicolaides KH. 2000b. First trimester markers of trisomy 21 and the influence of smoking status. Prenat Diagn 20: 852-853.
22. Spencer K, Crossley JA, Aifken DA, Nix AB, Dunstan FD, Williams K. 2002. Temporal changes in maternal serum biochemical markers of trisomy 21 across the first and second trimester of pregnancy. Ann Clin Biochem 39: 567-568.
23. Spencer K, Bindra R, Nicolaides KH. 2003a. Maternal weight correction of maternal serum PAPP-A and free beta-hCG MoM when screening for trisomy 21 in the first trimester of pregnancy. Prenat Diagn 23: 851-855.
24. Spencer K, Bindra R, Nix AB, Heath V, Nicolaides KH. 2003b. Delta-NT or NT MoM: which is the most appropriate method for calculating accurate patient-specific risks for trisomy 21 in the first trimester? Ultrasound Obstet Gynecol 22: 142-148.
25. Spencer K, Crossley JA, Aitken DA, Nix AB, Dunstan FD, Williams K. 2003c. The effect of temporal variation in biochemical markers of trisomy 21 across the first and second trimesters of pregnancy on the estimation of individual patient specific risks and the detection rates for Down's syndrome. Ann Clin Biochem 40: 219-231.
26. Vartiainen E, Seppala T, Lillsunde P, Puska P. 2002. Validation of self reported smoking by serum cotinine measurement in a community based study. J Epidemiol Community Health 56: 167-170.
27. Zdravkovic T, Genbacev O, McMaster MT, Fisher SJ. 2005. The adverse effects of maternal smoking on the human placenta: a review. Placenta 26(Suppl A): S81-S86.